C-VXCYHerophilus (prev System 1 Bio)
brain organoids, scaled biology, machine learning
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-VXCY
C-VXCYC-VXCYbrain organoids, scaled biology, machine learning
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The efforts to develop drugs for neurologic and psychiatric conditions has been plagued with failure. Herophilus is combining organoids derived from patient stem cells along with machine learning to gain new insight into the biology underlying these diseases and discover and develop more effective drugs. We spoke to Saul Kato, co-founder and CEO of Herophilus, about the drug development challenges for these diseases, how his company is using organoids and machine learning to better understand how to target them, and its growing pipeline therapeutic candidates.
A cleared NICO (neuro-immune cerebral organoid) used for neuroscience drug discovery at Herophilus.
Clay Finck chats with Frederic Kerrest about how he built Okta to be a multi-billion dollar company, how Okta was able to bounce back from a 70% revenue miss back in 2011, how Okta has been able to compete with big tech behemoths like Microsoft, his three rules for life, how he and his company is able to filter out the stock price to focus on the business, and much more! Frederic Kerrest is the Executive Vice Chairman, Chief Operating Officer and Co-Founder of Okta. He’s the author of “Zero to IPO,” a guide to building startups featuring insights from some of the world’s most successful and recognizable entrepreneurs. Alongside his roles at Okta, he also serves as Chairman and Co-Founder of Herophilus, a platform drug discovery company. IN THIS EPISODE, YOU’LL LEARN: 00:00 - Intro 01:37 - What Okta does and how it became a multi-billion dollar business. 03:43 - Why Frederic chose to stick with Okta after starting the company and helping it grow to over 5,000 employees. 10:30 - How
Herophilus Appoints Sharath Hegde, Ph.D. as Chief Scientific Officer as it Scales Drug Discovery Effort for Complex Brain Diseases Engineered Human Therapies Herophilus Appoints Sharath Hegde, Ph.D. as Chief Scientific Officer as it Scales Drug Discovery Effort for Complex Brain Diseases May 27, 2021 Leading "drug hunter" brings more than 30 years of drug discovery and development expertise, including as Recursion Pharmaceuticals’ CSO and Theravance’s SVP and Head of Research SAN FRANCISCO, Calif., May 27, 2021 -- Herophilus, a leading biotechnology company developing neurotherapeutics to cure
Sean Escola - Co-founder And Chief Neuroscientist at Herophilus | The Org Platform Enrich Pricing Log in Sign up Herophilus Sean Escola Unverified Sean Escola Co-founder And Chief Neuroscientist Contact Sean Escola is co-founder of Herophilus and an assistant professor in the Center for Theoretical Neuroscience and the Department of Psychiatry at Columbia University. His research, funded by the NIH and NSF, studies circuit models of motor function and learning. He is a co-founder of Herophilus, where he is involved in multiple aspects of the company’s scientific program. As a psychiatrist, D … es with a thesis in computational neuroscience, all at Columbia. He completed a residency in clinical psychiatry also at Columbia. Location New York, United States Org chart View org chart This person is not in the org chart Teams View all teams Consulting and Advisory 13 people, 0 jobs Offices View all offices This person is not in any offices Related people Suzanne Dann Wipro Vitor Henckel O2OBOTS Lidia Faustova FXSwede Emma Harris Dŵr Cymru Welsh Water Erin Avery Sharesies
Publications - Herophilus Home Our Approach Pipeline News Publications Reading Careers Publications. The team of scientists at Herophilus develops groundbreaking advancements in biotechnology and machine learning. We aim to publish and share our findings with the global research community to collectively advance the fields of neurobiology, disease research and drug discovery. Cell specificity of adeno-associated virus (AAV) serotypes in human cortical organoids 14 April 2023 bioRxiv Read More Using Cerebral Organoids to Develop MECP2-Activating Drugs for Rett Syndrome 24 March 2023 R
Sean Escola Toggle navigation about (current) blog publications cv Sean Escola Neuroscience. AI. Psychiatry. I have had the privilege of working in several diverse and interesting settings: I recently joined Protocol Labs as Neurotech and NeuroAI Lead. I co-founded Herophilus , a biotechnology company that combined patient-derived stem cell cultures (“organoids”) with advanced neuroassays and machine learning for drug discovery. As founding CEO in 2017–2020, I raised $30M in venture financing and hired a team of >40 scientists. We sold Herophilus’s technology to Genentech in 2023. I led a c … patients for medication management and psychotherapy. latest posts May 16, 2024 Proposal for a NeuroAI FRO selected publications Neuron Slow cortical dynamics generate context processing and novelty detection Yuriy Shymkiv, Jordan P Hamm, Sean Escola , and 1 more author Neuron , 2025 Abs Bib HTML PDF The cortex amplifies responses to novel stimuli while suppressing redundant ones. Novelty detection is necessary to efficiently process sensory information and build predictive m
WSJ: Biotech Startups Use Models of Human Organs for Drug Discovery - Herophilus Home Our Approach Pipeline News Publications Reading Careers WSJ: Biotech Startups Use Models of Human Organs for Drug Discovery. 20 April 2023 Excerpt: … San Francisco-based Herophilus created organoids to model the rare disorder Rett syndrome and used them to screen for compounds that turn on a gene that is silenced in patients with the neurological condition, said co-founder and Chief Executive Saul Kato. Herophilus, whose investors include 515 Ventures, aims to launch clinical trials next year,
Saul Kato SAUL KATO the separated-timescale biphasic filter is a ubiquitous feature of biological signal processing systems. Follow @neurotheory anything saulkato.com will get to me, eventually, with high probability. LINKS TO PUBLIC OUTPUT UCSF Profile Foundations of Cognition Lab Herophilus Google Scholar Medium Google Patent Search Kerowack on Spotify Captions can help clarify diagrams.
Herophilus Expands Scientific Advisory Board With Appointment of Kenneth Kosik, M.D. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Ca … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Herophilus Expands Scientific Advisory Board With Appointment of Kenneth Kosik, M.D. December 8, 2021 | 4 min read Twitter LinkedIn Facebook Email Print Herophilus today announced that the company is expanding its scientific advisory board with the appointment of Kenneth S. Kosik, M.A., M.D. … ution, and the biology of Alzheimer’s disease. He was awarded the 2021 Potamkin Prize for his work in Alzheimer’s research. “Understanding the complicated biology underlying neurological diseases is a critical part of the process of discovering and developing transformative medicines, and I believe Herophilus has the vision and technical capabilities to deliver long hoped-for advances,” said Dr. Kosik. With patient-derived stem cells, Herophilus develops brain organoids that … science and medicine with numerous awards including a Whitaker Health Sciences Award from the Massachusetts Institute of Technology and a Milton Foundation Award from Harvard Medical School. About Herophilus Herophilus is a San Francisco-based neurotherapeutics company focused on curing complex brain diseases. The company’s platform combines brain organoid science, systems neuroscience approaches, robotic automation, and advanced machine learning techniques to scale the abil … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Are Organoids... - Genetic Engineering & Biotechnology News Facebook Вход Публикация Genetic Engineering & Biotechnology News Genetic Engineering & Biotechnology News 6 март 2023 г. · Поделился/-ась с Доступно всем Are Organoids the Future of Drug Discovery? REGISTER: bit.ly/3SPgoUf A discussion of current research, challenges, and future directions. Don't miss our March 15 GEN Live, sponsored by Molecular Devices LLC , with our special guest Saul Kato, PhD, CEO of Herophilus. Все реакции: 8 1 комментарий Поделились: 1 Поставить "Нравится" Комментировать Самые актуал
Herophilus Appoints Brad Savall, Ph.D. as Vice President and Head of Chemistry as it Advances Pipeline of Novel Drugs for Complex Brain Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Herophilus Appoints Brad Savall, Ph.D. as Vice President and Head of Chemistry as it Advances Pipeline of Novel Drugs for Complex Brain Diseases January 25, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Herophilus, a leading biotechnology company developing neurotherapeutics to cure … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Herophilus : Saul Kato and Sharath Hegde - Built with Biology: Spaces | Podcast on Spotify
Our CEO Saul Kato and other industry leaders in the field discuss the road to new therapeutic approaches in AD. | Herophilus LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to jo
Herophilus : Saul Kato and Sharath Hegde - Built with Biology: Spaces - Podcast.co About Built with Biology: Spaces Herophilus : Saul Kato and Sharath Hegde S1E4 56:42 June 16th 2021 Play Subscribe Share Why haven't therapeutics for brain diseases improved in decades? Could new approaches using brian organoids (aka mini-brains on a chip!) advance the field and bring potential cures to millions in need? Listen to Saul Kato and Sharath Hegde of Herophilus explain why inspirations of the past may point the way forward to a huge leap in treatments for brain disease. Want to ask your question live
Frédéric Kerrest - Co-Founder & Director at Herophilus | The Org Platform Enrich Pricing Log in Sign up Herophilus Frédéric Kerrest Unverified Frédéric Kerrest Co-Founder & Director Contact Frederic Kerrest is co-founder and board director of Herophilus, and the Executive Vice Chairman, Chief Operating Officer, and Co-Founder of Okta. Prior to Okta, Frederic worked in sales and business development at Salesforce.com, and in venture capital at Hummer Winblad Venture Partners. Frederic is the author of Zero to IPO, a guide to building startups based on his own experiences and those of … ost successful and recognizable entrepreneurs. The book was an outgrowth of his award-winning podcast of the same name, which features Silicon Valley founders, investors, and entrepreneurs sharing insights from their experiences building businesses. He serves on the Martin Trust Center for MIT Entrepreneurship Executive Advisory Board and advises early stage software companies. Frederic earned a B.S. in computer science from Stanford University, and an M.B.A. in Entrepreneurs … Management, where he was the 2008 MIT Patrick J. McGovern, Jr. Entrepreneurship Award recipient. Org chart View org chart This person is not in the org chart Teams View all teams Consulting and Advisory 13 people, 0 jobs Leadership Team 2 people, 0 jobs Offices View all offices This person is not in any offices Related people Sangeeta Chhabra Ace Cloud Hosting Brijesh Tekrawala Differenz System Fazil Loladia Differenz System Nicole Hendrix BRIC Foundation Gary Sims Venturezen
Frederic Kerrest, Okta @ Entrepreneurial Thought Leader Speaker Series (ETL) - Stanford University --> --> Skip to main content Stanford University Stanford Events Calendar Search Search --> Log in Get help Log in Sign up Menu Events: --> Featured Events Today's Events Events By Date < Current Month > Su Mo Tu We Th Fr Sa Javascript must be enabled Departments Groups Places Stanford University Past Events Frederic Kerrest, Okta @ Entrepreneurial Thought Leader Speaker Series (ETL) Close modal Lecture/Presentation/Talk Frederic Kerrest, Okta @ Entrepreneurial Thought Leader Speaker Series … ’s most successful and recognizable entrepreneurs. He’s also the co-host of the award-winning “Zero to IPO” podcast, featuring founders, entrepreneurs, and investors sharing insights from their experiences building innovative technology companies. Kerrest is also chairman and co-founder of Herophilus, a platform drug discovery company, and partner and founder of The Operator Network angel investment group, where he enjoys advising early-stage software company founders. Prior
Herophilus conducts in vivo studies of HRP-12975 for Rett syndrome | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscap
CV Alex Rogozhnikov --> Alex Rogozhnikov Email: name . secondname [email protected] Blog: Brilliantly wrong Github: arogozhnikov Google Scholar: Alex Rogozhnikov Education and Career 2024-now — founding engineer and AI tech lead at Chai Discovery 2022-2024 — founding engineer/head of data science at Parallel Biosystems 2019-2022 — principal ML scientist at Herophilus (acquired by Genentech) 2017-2018 — leading research engineer at Samsung Research 2014-2017 — research scientist at Yandex (leading search engine in Russia), worked on joint research projects with CERN 2 … ide a mountain in Italy, it was created to confirm neutrino oscillations (Nobel prize 2015). In this project I've created a system that detects electromagnetic showers in the data collected by the OPERA. That is, among millions of base tracks it finds a small pattern of ~ hundred base tracks. Needle-in-a-hay problem with tough computational requirements. Read more Reweighting with Boosted Decision Trees An important problem of many analyses in high energy physics is a discrep